A clinical trial showed that the PD-L1 inhibitor avelumab and the PD-1 inhibitor pembrolizumab plus axinib with that of sunitinib had better advantages on RCC compared to sunitinib (9). The gene discussed is PDCD1; the disease is renal cell carcinoma.